Compare BIO-TECHNE Corp (TECH) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United States Oil ETF — how do they compare? BIO-TECHNE Corp trades at $71.57 (market cap $11.16B), while United States Oil ETF trades at $128.96. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while United States Oil ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| TECH | USO | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $152.96 |
52-Week Low | $43.31 | $66.17 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
USO is trading at $125.51, up 1.25% with strong bullish momentum driven by Middle East supply disruptions. Technical indicators show overall bullish sentiment with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Recent news highlights escalating geopolitical tensions in the Strait of Hormuz, pushing oil prices higher and benefiting the fund's performance.
The outlook remains positive as supply constraints and geopolitical risks continue to support oil prices, though overbought technical conditions warrant caution. Key risks include potential conflict de-escalation and OPEC demand adjustments. Current momentum favors continued strength, but volatility remains elevated due to geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
